PriceTargets.com logo

Alpha Tau Medical - DRTS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 248.58%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.30 As of 11/20/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for DRTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alpha Tau Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DRTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DRTS

Analyst Price Target is $8.00
▲ +248.58% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Alpha Tau Medical in the last 3 months. The average price target is $8.00, with a high forecast of $9.00 and a low forecast of $7.00. The average price target represents a 248.58% upside from the last price of $2.30.

This chart shows the closing price for DRTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Alpha Tau Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
10/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
8/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
8/15/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.00
6/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
5/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00
5/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00
12/15/2023CitigroupInitiated CoverageBuy$8.00
11/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$9.00
11/17/2023Piper SandlerLower TargetOverweight ➝ Overweight$12.00 ➝ $8.00
9/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$9.00
8/29/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$23.00
8/29/2023HC WainwrightReiterated RatingBuy ➝ Buy$9.00
8/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$9.00
4/24/2023HC WainwrightInitiated CoverageBuy$9.00
11/23/2022Piper SandlerLower TargetOverweight$19.00 ➝ $12.00
4/14/2022Cantor FitzgeraldInitiated CoverageOverweight$20.00
4/8/2022Piper SandlerInitiated CoverageOverweight$19.00
4/4/2022CitigroupInitiated CoverageBuy$21.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Alpha Tau Medical logo
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Read More

Today's Range

Now: $2.30
Low: $2.27
High: $2.32

50 Day Range

MA: $2.28
Low: $2.17
High: $2.45

52 Week Range

Now: $2.30
Low: $1.75
High: $3.40

Volume

13,220 shs

Average Volume

23,520 shs

Market Capitalization

$159.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Alpha Tau Medical?

The following Wall Street sell-side analysts have issued reports on Alpha Tau Medical in the last year: Citigroup Inc., HC Wainwright, and Piper Sandler.
View the latest analyst ratings for DRTS.

What is the current price target for Alpha Tau Medical?

0 Wall Street analysts have set twelve-month price targets for Alpha Tau Medical in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 248.6%. HC Wainwright has the highest price target set, predicting DRTS will reach $9.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $7.00 for Alpha Tau Medical in the next year.
View the latest price targets for DRTS.

What is the current consensus analyst rating for Alpha Tau Medical?

Alpha Tau Medical currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DRTS will outperform the market and that investors should add to their positions of Alpha Tau Medical.
View the latest ratings for DRTS.

What other companies compete with Alpha Tau Medical?

Other companies that are similar to Alpha Tau Medical include OrthoPediatrics, AxoGen, Semler Scientific, SI-BONE and Treace Medical Concepts. Learn More about companies similar to Alpha Tau Medical.

How do I contact Alpha Tau Medical's investor relations team?

Alpha Tau Medical's physical mailing address is 301 N. MARKET STREET STE 1414, WILMINGTON DE, 19801. The company's listed phone number is 972-3577-4115 and its investor relations email address is [email protected]. The official website for Alpha Tau Medical is healthcarecapitalcorp.com. Learn More about contacing Alpha Tau Medical investor relations.